Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your lifestyle or genes cause lung cancer before 50? new study investigates.

NCT ID NCT04640259

Knowledge-focused Sponsor: Addario Lung Cancer Medical Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This 100% remote study surveys 250 people diagnosed with non-small cell lung cancer before age 50. Participants answer questions about their environment, lifestyle, and family history, and may donate blood. The goal is to uncover factors linked to genetic changes that drive young lung cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify risk factors and genetic patterns that lead to lung cancer in younger people, potentially guiding future prevention or early detection strategies.
What could go wrong
This is an observational study, not a treatment trial. It relies on self-reported surveys and voluntary blood samples, which may have biases or limited data. Results may not directly change care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

187 people

The number who actually took part.

Started

Feb 2021

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A minimum of 250 subjects distributed with at least 50 subjects among the most common driver mutation groups will be enrolled into the study: 1. EGFR (del19 and L858R) - 50 subjects 2. ROS1 - 50 subjects 3. ALK - 50 subjects 4. KRAS - 50 subjects 5. Other Groups: 1. Uncommon activating mutation for which specific targeted therapy exists (RET fusion, NTRK fusion, BRAF V600E, MET Exon14 skipping mutations, other activating EGFR mutations) - 25 subjects 2. Non-targetable other mutations (p53, NF1, ATM, PIK3CA, RB, non-V600E BRAF, NTRK mutation) or no identified mutation. - 25 subjects Subjects with more than one mutation will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female aged 18 years and over; or the age of majority for their residential state at the time of enrollment 2. Documentation of primary NSCLC, any stage 3. Less than 50 years of age at the time of NSCLC diagnosis 4. Documentation of testing by a CLIA certified lab for genomic drivers of lung cancer 5. Willingness to undergo all study procedure 6. Provision of written informed consent Exclusion Criteria: 1. Male or female aged less than 18 years; or less than the age of majority for their residential state 2. Greater than or equal to 50 years of age at the time of NSCLC diagnosis 3. No documentation of mutation testing 4. Unwilling to undergo all study procedures 5. Unable or unwilling to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

  • Addario Lung Cancer Medical Institute

    San Carlos, California, 94070, United States

  • USC Keck School of Medicine

    Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.